Switch theme
Sign up to access all valuation multiples
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
2018
195
LTM Revenue $4.7M
LTM EBITDA -$129M
-$73.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TScan Therapeutics has a last 12-month revenue (LTM) of $4.7M and a last 12-month EBITDA of -$129M.
In the most recent fiscal year, TScan Therapeutics achieved revenue of $2.8M and an EBITDA of -$120M.
TScan Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TScan Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.7M | XXX | $2.8M | XXX | XXX | XXX |
| Gross Profit | $4.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$129M | XXX | -$120M | XXX | XXX | XXX |
| EBITDA Margin | -2731% | XXX | -4252% | XXX | XXX | XXX |
| EBIT | -$141M | XXX | -$135M | XXX | XXX | XXX |
| EBIT Margin | -2985% | XXX | -4788% | XXX | XXX | XXX |
| Net Profit | -$135M | XXX | -$127M | XXX | XXX | XXX |
| Net Margin | -2857% | XXX | -4528% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, TScan Therapeutics's stock price is $1.
TScan Therapeutics has current market cap of $80.9M, and EV of -$73.7M.
See TScan Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$73.7M | $80.9M | XXX | XXX | XXX | XXX | $-1.18 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, TScan Therapeutics has market cap of $80.9M and EV of -$73.7M.
TScan Therapeutics's trades at -26.2x EV/Revenue multiple, and 0.6x EV/EBITDA.
Equity research analysts estimate TScan Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TScan Therapeutics has a P/E ratio of -0.6x.
See valuation multiples for TScan Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $80.9M | XXX | $80.9M | XXX | XXX | XXX |
| EV (current) | -$73.7M | XXX | -$73.7M | XXX | XXX | XXX |
| EV/Revenue | -15.6x | XXX | -26.2x | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/Gross Profit | -15.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTScan Therapeutics's last 12 month revenue growth is 62%
TScan Therapeutics's revenue per employee in the last FY averaged $14K, while opex per employee averaged $0.7M for the same period.
TScan Therapeutics's rule of 40 is -319% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TScan Therapeutics's rule of X is -2577% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TScan Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 62% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -2731% | XXX | -4252% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 32% | XXX | XXX | XXX |
| Rule of 40 | -319% | XXX | -4190% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2577% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $14K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3812% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4888% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TScan Therapeutics acquired XXX companies to date.
Last acquisition by TScan Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . TScan Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was TScan Therapeutics founded? | TScan Therapeutics was founded in 2018. |
| Where is TScan Therapeutics headquartered? | TScan Therapeutics is headquartered in United States of America. |
| How many employees does TScan Therapeutics have? | As of today, TScan Therapeutics has 195 employees. |
| Who is the CEO of TScan Therapeutics? | TScan Therapeutics's CEO is Dr. Gavin MacBeath, PhD. |
| Is TScan Therapeutics publicy listed? | Yes, TScan Therapeutics is a public company listed on NAS. |
| What is the stock symbol of TScan Therapeutics? | TScan Therapeutics trades under TCRX ticker. |
| When did TScan Therapeutics go public? | TScan Therapeutics went public in 2021. |
| Who are competitors of TScan Therapeutics? | Similar companies to TScan Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of TScan Therapeutics? | TScan Therapeutics's current market cap is $80.9M |
| What is the current revenue of TScan Therapeutics? | TScan Therapeutics's last 12 months revenue is $4.7M. |
| What is the current revenue growth of TScan Therapeutics? | TScan Therapeutics revenue growth (NTM/LTM) is 62%. |
| What is the current EV/Revenue multiple of TScan Therapeutics? | Current revenue multiple of TScan Therapeutics is -15.6x. |
| Is TScan Therapeutics profitable? | Yes, TScan Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of TScan Therapeutics? | TScan Therapeutics's last 12 months EBITDA is -$129M. |
| What is TScan Therapeutics's EBITDA margin? | TScan Therapeutics's last 12 months EBITDA margin is -2731%. |
| What is the current EV/EBITDA multiple of TScan Therapeutics? | Current EBITDA multiple of TScan Therapeutics is 0.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
